KAHF Biotech is Redefining the Future of Cancer Treatment Through Next-Generation Therapeutic Platforms Targeting Aggressive, Metastatic, and Dormant Tumors.

Next-Generation Therapeutic Platform Focused on Advancing Innovative Targeted Therapies For Cancer Treatment.

Dormant Cancer

Dormant cancer cells are tumor cells that lie inactive in the body-often undetectable and resistant to conventional therapies. Though silent, they can awaken months or even years later to cause relapse and metastasis. At KAHF Biotech, we believe targeting these elusive cells is key to achieving long-term remission and true cancer cures. By focusing on dormant and metastatic cells, we aim to rewrite the future of cancer therapy-one that prevents recurrence before it begins.

Metastatic Tumor

Metastatic tumors arise when cancer cells spread from the original tumor to distant organs, forming new, often aggressive growths. These tumors are responsible for the vast majority of cancer deaths and are notoriously difficult to treat. At KAHF Biotech, we are committed to targeting the root drivers of metastasis to stop cancer where it becomes most dangerous.

Technologies

At KAHF Biotech, Inc., we harness the precision of monoclonal antibodies and the gene-silencing power of Dicer-substrate siRNA (DsiRNA) to selectively attack our discovered targets in dormant and metastatic tumor cells-addressing the root drivers of relapse and therapeutic resistance

KAHF Biotech, Inc.

Collaboration

We Invite Visionary Investors to Join Us in Advancing This Bold New Frontier in Oncology.

OUR MISSION

At KAHF Biotech, Inc., we are driven by a simple, yet profound truth: cancer patients deserve more than the silence of being told, “There’s nothing more we can do.” Our name is rooted in the timeless story of KAHF-a story of resilience, refuge, and unwavering faith in the face of great adversity. Just as the youths sought shelter in a cave and were granted protection and time, we strive to offer a refuge for patients and families navigating the storm of cancer.

We believe that every scientific breakthrough is a form of divine timing-that healing comes through both persistence and trust in a higher plan. Our work is more than just medicine; it is a mission to bring hope, strength, and life-saving innovation to those who need it most.

At KAHF Biotech, Inc., we are on a relentless mission to Chase, Capture, and Eliminate metastatic cancer cells. We chase new frontiers in cancer therapy, targeting metastatic disease with cutting-edge research and innovation. We capture cancer with pinpoint accuracy, ensuring our therapies reach the heart of the disease. And, most importantly, we eliminate it-bringing life-saving solutions to those who have run out of options.

Motto: Chase, Capture, Eliminate

KAHF Biotech is in preliminary stage of development. The mission of company is to open a new avenue for treatment and prevention of cancer metastasis. The company’s focus is on Cancer Metastasis Prevention and Elimination.

Mission Statement

Our mission is to establish KAHF Biotech as an industry leader in the development of innovative therapies for cancer treatment, with a particular focus on metastatic disease and aggressive cancers with significant unmet medical need. We are committed to advancing transformative therapeutic approaches that aim to improve patient outcomes, expand treatment possibilities, and bring hope to patients and families facing some of the most challenging forms of cancer.

Vision

Our vision is to become a global leader in cancer therapeutics by revolutionizing the treatment of metastatic and aggressive cancers through the development of impactful, effective, and accessible therapies. We strive to overcome the challenges associated with advanced disease and deliver innovative treatment solutions to patients worldwide, improving survival, quality of life, and long-term outcomes for those facing cancer — especially those who need them most, no matter where they are.

OUR SKILLS

Cancer Therapeutic Development and Discovery

Preclinical Development

IND-enabling Studies

Clinical Trials

Cancer Therapeutic Development Particularly Metastatic and Dormant Cancer Cells

KAHF Biotech, Inc.

HOURS OF WORK

FINISHED WORKS

CLIENTS

SOCIAL FOLLOWERS

Collaborators

The science driving KAHF BIOTECH, INC. is supported through collaborations with leading institutions, including the NCI-designated Wilmot Cancer Institute at the University of Rochester Medical Center and Sino Biological, a global leader in recombinant protein production and antibody development.

KAHF Biotech, Inc. 2025